Get started
Author

Maeve Waldron-Lynch

Observed names: M Waldron-Lynch, M. G. Waldron-Lynch, M. Waldron-Lynch, Maeve G. Waldron-Lynch, Waldron-Lynch, M., Waldron-Lynch, Maeve
Observed institutions: Novartis (Switzerland), BC Cancer Agency, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, University of British Columbia, University of Cologne, Genentech, University of Milan, University of Utah, Georgetown University Medical Center, Royal Bournemouth Hospital, Auckland City Hospital, Institut Gustave Roussy, University Hospital Heidelberg, Yale University, Tango Therapeutics (United States), Institute of Oncology Prof. Dr. Ion Chiricuta, Instituto Português de Oncologia Francisco Gentil, National Center for Tumor Diseases, Roche (United Kingdom), Universitätsmedizin Göttingen, Hospital Universitario de La Princesa, Centre Antoine Lacassagne, University Hospital Cologne, European Institute of Oncology, University of Göttingen, Bournemouth University
OpenAlex ID: A5078425798
Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer
2020 · Jürgen Wolf, Takashi Seto, et al. · New England Journal of Medicine · 1,003
PDF
Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer
2017 · Andreas Schneeweiss, Stephen Chia, et al. · European Journal of Cancer · 275
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study
2017 · S.M. Swain, M.S. Ewer, et al. · Annals of Oncology · 246
PDF
Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.
2019 · Juergen Wolf, Takashi Seto, et al. · Journal of Clinical Oncology · 111
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature
2009 · Edward James, Maeve G. Waldron-Lynch, et al. · Anti-Cancer Drugs · 46
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
2017 · S.M. Swain, A. Schneeweiss, et al. · Annals of Oncology · 41
PDF
Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
2018 · J. Wolf, T. Seto, et al. · Annals of Oncology · 40
PDF
Capmatinib in patients with high-level MET -amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.
2020 · Juergen Wolf, Tobias R. Overbeck, et al. · Journal of Clinical Oncology · 27
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study
2023 · David Belada, Katerina Kopeckova, et al. · Blood · 22
PDF
Abstract CT082: Capmatinib in METex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRY mono-1 study, including efficacy in patients (pts) with brain metastases (BM)
2020 · Edward B. Garon, Rebecca S. Heist, et al. · Cancer Research · 20
Cmet-22. Capmatinib (inc280) in Metδex14-mutated Advanced Non-small Cell Lung Cancer (nsclc): Efficacy Data From the Phase 2 Geometry Mono-1 Study
2019 · Rebecca S Heist, Takashi Seto, et al. · Neuro-Oncology · 17
Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.
2020 · Harry J.M. Groen, Wallace L. Akerley, et al. · Journal of Clinical Oncology · 10
1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 study
2020 · J.F. Vansteenkiste, E.F. Smit, et al. · Annals of Oncology · 9
PDF
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review
2023 · Jürgen Wolf, Pierre-Jean Souquet, et al. · Clinical Lung Cancer · 8
PDF
Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
2022 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Blood · 7
First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
2022 · Grzegorz S. Nowakowski, Johannes Duell, et al. · Blood · 7
frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.
2022 · Umberto Vitolo, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology · 6
OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study
2019 · R.S. Heist, J. Wolf, et al. · Journal of Thoracic Oncology · 5
PDF
Abstract P4-21-41: Primary analysis of BERENICE: A phase II cardiac safety study of pertuzumab, trastuzumab, and neoadjuvant anthracycline-based chemotherapy in patients with locally advanced, inflammatory, or early-stage, unilateral, and invasive HER2-positive breast cancer
2017 · SM Swain, MS Ewer, et al. · Cancer Research · 5
Pb2113: Frontmind: a Phase Iii, Randomized, Double-blind Study of Tafasitamab + Lenalidomide + R-chop Vs R-chop Alone for Newly Diagnosed High-intermediate and High-risk Diffuse Large B-cell Lymphoma
2022 · U. Vitolo, G. S. Nowakowski, et al. · HemaSphere · 3
Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA)
2017 · A Schneeweiss, S Chia, et al. · Cancer Research · 3
P85.04 Capmatinib in Patients with METex14-Mutated Non-Small Cell Lung Cancer: GEOMETRY Mono-1 Asian Subgroup Analysis
2021 · J. Han, J. Wolf, et al. · Journal of Thoracic Oncology · 2
PDF
Capmatinib (INC280) in patients (pts) with METex14-mutated advances NSCLC: an update from phase 2 GEOMETRY mono-1 study
2020 · J Wolf, T Seto, et al. · Pneumologie · 2
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
2018 · S.M. Swain, A. Schneeweiss, et al. · Annals of Oncology · 2
PDF
Stage and grade of colorectal cancer at presentation in the West of Ireland
2008 · D. McKeown, M. G. Waldron-Lynch, et al. · Journal of Clinical Oncology · 2
Works count: 42
Citation count: 1,923
H-index: 11
I10-index: 12
Year
Topic
Type